New perspectives on the role of sphingosine 1-phosphate in cancer

Handbook of Experimental Pharmacology

Volumn 216, Issue , 2013, Pages 55-71

  Pyne, Susan ^a   Pyne, Nigel J ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Cancer; Sphingosine 1 phosphate; Sphingosine kinase

Indexed keywords

ABC 294640; ANTINEOPLASTIC AGENT; FINGOLIMOD; LYASE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE LYASE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2; UNCLASSIFIED DRUG; DRUG DERIVATIVE; LYSOPHOSPHOLIPID; PHOSPHOTRANSFERASE; PROTEIN KINASE INHIBITOR; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE LYASE (ALDOLASE); SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE 1-PHOSPHATE LYASE (ALDOLASE); SPHINGOSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BCR ABL1 GENE; CARCINOGENESIS; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; KIDNEY CARCINOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY; REVIEW;

ALDEHYDE-LYASES; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOID; LYSOPHOSPHOLIPIDS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; NEOPLASMS; ONCOGENES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN KINASE INHIBITORS; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE;

MLCS; MLOWN;

EID: 84880537308     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-7091-1511-4_3     Document Type: Article

References (65)

1. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, Maceyka M, Jiang H, Luo C, Kordula T, Milstien S, Spiegel S (2010) Sphingosine 1-phosphate is a missing co-factor for the E3 ligase TRAF2. Nature 465:1084-1088
2. Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, Rhodes LV, Ashe HB, Wiese TE, Smith CD, Burow ME, Beckman BS (2010) Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 151:5124-5135
3. Antoon JW, Meacham WD, Bratton MR, Slaughter EM, Rhodes LV, Ashe HB, Wiese TE, Burow ME, Beckman BS (2011) Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signalling in human breast cancer. J Mol Endocrinol 46:205-216
4. Arnold HK, Sears RC (2008) A tumor suppressor role for PP2A-alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev 27:147-158
5. Azuma H, Takahara S, Ichimaru N, Wang JD, Itoh Y, Otsuki Y, Morimoto J, Fukui R, Hoshiga M, Ishihara T, Nonomura N, Suzuki S, Okuyama A, Katsuoka Y (2002) Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res 62:1410-1419
6. Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM, Ogretmen B (2007) Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib induced apoptosis in K562 human chronic myeloid lekaemia cells. J Biol Chem 282:10922-10934
7. Barr RK, Lynn HE, Moretti PA, Khew-Goodall Y, Pitson SM (2008) Deactivation of sphingosine kinase 1 by protein phosphatase 2A. J Biol Chem 283:34994-35002
8. Beljanski V, Knaak C, Smith CD (2010) A novel sphingosine kinase inhibitor induces autophagy in tumour cells. J Pharmacol Exp Ther 333:454-464
9. Bonhoure E, Lauret A, Barnes DJ, Martin C, Malavaud B, Kohama T, Melo JB, Cuvillier O (2008) Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukaemia cells. Leukemia 22:971-979
10. Colie S, Van Veldhoven PP, Kedjouar B, Bedia C, Albinet V, Sorli SC, Garcia V, Djavaheri- Mergny M, Bauvy C, Codogno P, Levade T, Andrieu-Abadie N (2009) Disruption of sphingosine 1-phosphate lyase confers resistance to chemotherapy and promotes oncogenesis through Bcl-2/Bcl-xL upregulation. Cancer Res 69:9346-9353
11. Dickson MA, Carvajal RD, Merrill Jr. A.H., Gonen M, Cane LM, Schwartz GK (2011) A phase I clinical trial of safingol in combination with Cisplatin in advanced solid tumours. Clin Cancer Res 17:2484-2492
12. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221
13. Fisher KE, Pop A, Koh W, Anthis NJ, Saunders WB, Davis GE (2006) Tumour cell invasion of collagen matrices requires coordinate lipid agonist-induced G protein and membrane-type matrix metalloproteinase-1-dependent signalling. Mol Cancer 5:69
14. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JLM, Yun JK, Smith CD (2003) Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 63:5962-5969
15. French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, Upson JJ, Green CL, Keller SN, Smith CD (2010) Pharmacology and antitumour activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 333:129-139
16. Gao P, Smith CD (2011) Ablation of sphingosine kinase-2 inhibits tumour cell proliferation and migration. Mol Cancer Res 9(11):1509-19
17. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S, Spiegel S (2009) Regulation of histone acetylation in the nucleus by sphingosine 1-phosphate. Science 325:1254-1257
18. Heffernan-Stroud LA, Helke KL, Jenkins RW, De Costa AM, Hannum YA, Obeid LM (2011) Defining a role for sphingosine kinase 1 in p53-dependent tumours. Oncogene 31(9):1166-75
19. Huwlier A, Kotelevets N, Xin C, Pastukhov O, Pfeilschiffter J, Zangemeister-Wittke U (2011) Loss of sphingosine kinase 1 in carcinoma cells increases formation of reactive oxygen species and sensitivity to doxorubicin-induced DNA damage. Br J Pharmacol 162:532-543
20. Ito H, Yoshida K, Murakami M, Hagiwara K, Sasaki N, KobayashiM, TakagiA, Kojima T, Sobue S, Suzuki M, Tamiya-Koizumi K, Nakamura M, Banno Y, Nozawa Y, Murate T (2011) Heterogeneous sphingosine-1-phosphate lyase gene expression and its regulatory mechanism in human lung cancer cell lines. Biochim Biophys Acta 1811:119-128
21. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA (1994) Tumour spectrum analysis in p53-mutant mice. Curr Biol 4:1-7
22. Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK, Zipkin RE, Dent P, Kordula T, Milstien S, Spiegel S (2009) Targeting sphingosine kinase 1 inhibits AKT signalling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res 69:6915-6923
23. Kennedy AJ, Mathews TP, Kharel Y, Field SD, Moyer ML, East JE, Houck JD, Lynch KR, Macdonlad TL (2011) Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells. J Med Chem 54:3524-3548
24. Kilbey A, Terry A, Jenkins A, Borland G, Zhang Q, Wakelam MJ, Cameron ER, Neil JC (2010) Runx regulation of sphingolipid metabolism and survival signalling. Cancer Res 70:5860-5869
25. Kono K, Tanaka M, Ogita T, Kohama T (2000a) Characterisation of B-5354c, a new sphingosine kinase inhibitor, produced by a marine bacterium. J Antibiot (Tokyo) 53:759-764
26. Kono K, Tanaka M, Ogita T, Hosoya T, Koyama T (2000b) F-12509A, a new sphingosine kinase inhibitor, produced by a discomycete. J Antibiot (Tokyo) 53:459-466
27. Kono K, Tanaka M, Ono Y, Hosoya T, Ogita T, Kohama T (2001) S-15183a and b, new sphingosine kinase inhibitors, produced by a fungus. J Antibiot (Tokyo) 54:415-420
28. Leclercq TM, Moretti PA, Pitson SM (2011) Guanine nucleotides regulate sphingosine kinase 1 activation by eukaryotic elongation factor 1A and provide a mechanism for eEF1A-associated oncogenesis. Oncogene 30:372-378
29. Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, Kortylewski M, Horne D, Somlo G, Forman S, Jove R, Yu H (2010) STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 16:1421-1428
30. Li QF, Huang WR, Duan HF, Wang H, Wu CT, Wang LS (2007) Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells. Oncogene 26:7904-7908
31. Lim KG, Tonelli F, Li Z, Lu X, Bittman R, Pyne S, Pyne NJ (2011a) FTY720 analogues as sphingosine kinase 1 inhibitors: Enzyme inhibition kinetics, allosterism, proteasomal degradation and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem 286:18633-18640
32. Lim KG, Sun C, Bittman R, Pyne NJ, Pyne S (2011b) (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cell Signal 23:1590-1595
33. Liu H, Toman RE, Goparaju SK, Maceyka M, Nava VE, Sankala H, Payne SG, Bektas M, Ishii I, Chun J, Milstien S, Spiegel S (2003) Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J Biol Chem 278:40330-40336
34. Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, Muthusamy N, Byrd JC (2008) FTY720 demonstrates promising pre-clinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 111:275-284
35. Long JS, Edwards J, Watson C, Tovey S, Mair K, Schiff R, Natarajan V, Pyne NJ, Pyne S (2010a) Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor positive breast cancer cells. Mol Cell Biol 30:3827-3841
36. Long JS, Fujiwara Y, Edwards J, Tannahill C, Tigyi G, Pyne S, Pyne NJ (2010b) Sphingosine 1-phosphate 4 uses HER2 (ErbB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. J Biol Chem 285:35957-35966
37. Loveridge C, Tonelli F, Leclecq T, Lim KG, Long S, Berdyshev E, Tate RJ, Natarajan V, Pitson SM, Pyne NJ, Pyne S (2010) The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4- (p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J Biol Chem 285:38841-38852
38. Lozano G (2010) Mouse models of p53 functions. Cold Spring Harb Perspect Biol 2(4):a001115
39. Marfe G, Di Stefano C, Gambacurta A, Ottone T, Martini V, Abruzzese E, Mologni L, Sinibaldi- Salimei P, de Fabritis P, Gambacorti-Passerini C, Amadori S, Birge RB (2011) Sphingosine kinase 1 overexpression is regulated by signalling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. Exp Hematol 39:653-665.e6
40. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D (2005) The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8:355-368
41. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R,Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen C-S, Verrills NM, Roy DC, CaligiuriMA, Bloomfield CD, Byrd JC, Perrotti D (2007) FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 117:2408-2421
42. Omar HA, Chou CC, Berman-Booty LD, Ma Y, Hung JH, Wang D, Kogure T, Patel T, Terracciano L, Muthusamy N, Byrd JC, Kulp SK, Chen CS (2011) Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology 53:1943-1958
43. Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissie J, Malavaud B, Waxman J, Cuvillier O (2010) FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res 70:8651-8661
44. Pitman MR, Barr RK, Gliddon BL, Magarey AM, Moretti PA, Pitson SM (2011) A critical role for the protein phosphatase 2A B'alpha regulatory subunit in dephosphorylation of sphingosine kinase 1. Int J Biochem Cell Biol 43:342-347
45. Pitson SM, Moretti PA, Zebol JR, Lynn HE, Xia P, Vadas MA, Wattenberg BW (2003) Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J 22:5491-5500
46. Pyne S, Pyne NJ (2000) Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 349:385-402
47. Pyne NJ, Pyne S (2010) Sphingosine 1-phosphate and cancer. Nat Rev Cancer 10:489-503
48. Pyne S, Lee SC, Long J, Pyne NJ (2009) Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cell Signal 21:14-21
49. Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, Obeid LM, El-Shewy HM, Oaks J, Santhanam R, Marcucci G, Baran Y, Mahajan S, Fernandes D, Stuart R, Perrotti D, Ogretmen B (2011) Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr/Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood 117:5941-5952
50. Sankala HM, Hait NC, Paugh SW, Shida D, Lepine S, Elmore LW, Dent P, Milstien S, Spiegel S (2007) Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res 67:10466-10474
51. Shida D, Kitayama J, Yamaguchi H, Yamashita H, Mori K, Watanabe T, Nagawa H (2005) Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells. Biochem Biophys Res Commun 327:907-914
52. Shirai K, Kaneshiro T, Wada M, Furuya H, Bielawski J, Hannun YA, Obeid LM, Ogretmen B, Kawamori T (2011) A role of sphingosine kinase 1 in head and neck carcinogenesis. Cancer Prev Res 4:454-462
53. Sobue S, Nemoto S, Murakami M, Ito H, Kimura A, Gao S, Furuhata A, Takagi A, Kojima T, Nakamura M, Ito Y, Suzuki M, Banno Y, Nozawa Y, Murati T (2008) Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukaemia cells. Int J Haematol 87:266-275
54. Sukocheva O, Wadham C, Holmes A, Albanese N, Verrier E, Feng F, Bernal A, Derian CK, Ullrich A, Vadas MA, Xia P (2006) Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol 173:301-310
55. Taha TA, Osta W, Kozhaya L, Bielawski J, Johnson KR, Gillanders WE, Dbaibo GS, Hannun YA, Obeid LM (2004) Downregulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J Biol Chem 279:20546-20554
56. Tonelli F, Lim KG, Loveridge C, Long J, Pitson SM, Tigyi G, Bittman R, Pyne S, Pyne NJ (2010) FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal 22:1536-1542
57. Valentine WJ, Kiss GN, Liu J, Gotoh M, Murakami-Murofushi K, Pham TC, Baker DL, Parrill AL, Lu X, Sun C, Bittman R, Pyne NJ, Tigyi G (2010) (S)-FTY720-vinylphosphonate, an analogue of the immunosuppressive agent FTY720, signals as a pan-antagonist of sphingosine 1-phosphate GPCR and inhibits autotaxin activity. Cell Signal 22:1543-1553
58. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW (2005) Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: role of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 64:695-705
59. Wallington-Beddoe CT, Hewson J, Bradstock KF, Bendall LJ (2011) FTY720 produces caspaseindependent cell death of acute lymphoblastic leukemia cells. Autophagy 7:707-715
60. Watson C, Long JS, Orange C, Tannahill CL, Mallon E,McGlynn LM, Pyne S, Pyne NJ, Edwards J (2010) High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol 177:2205-2215
61. Xia P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW, D'Andrea RJ, Vadas MA (2000) An oncogenic role of sphingosine kinase. Curr Biol 10:1527-1530
62. Yamashita H, Kitayama J, Shida D, Yamaguchi H,Mori K, OsadaM, Aoki S, Yatomi Y, Takuwa Y, Nagawa H (2006) Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: differential regulation on the migration and proliferation. J Surg Res 130:80-87
63. Yasui H, Hideshima T, Raje N, Roccaro AM, Shiraishi N, Kumar S, Hamasaki M, Ishitsuka K, Tai YT, Podar K, Catley L, Mitsiades CS, Richardson PG, Albert R, Brinkmann V, Chauhan D, Anderson KC (2005) FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res 65:7478-7484
64. Zhang N, Qi Y, Wadham C, Wang L, Warren A, Di W, Xia P (2010) FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy. Autophagy 6:1157-1167
65. Zheng T, Meng X, Wang JB, Chen X, Yin D, Liang Y, Song X, Pan S, Jiang H, Liu L (2010) PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. J Cell Biochem 111:218-228